Thea Loise Woodward
Sherlock Biosciences has received a contract from the U.S. Defense Threat Reduction Agency to create diagnostic tests for military service members to detect infectious disease agents and other biothreats on the battlefield.
The company said Thursday it will use multiyear grant funding from DTRA to further develop bioinformatics and deep learning tools designed to accelerate molecular test definition and deployment efforts.
Sherlock aims to produce biothreat diagnostics through a synthetic biology platform and a gene-editing system called clustered regularly interspaced short palindromic repeats.
The biotechnology firm noted its CRISPR-based approach seeks to identify and quantify DNA sequences.
